Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis

A longitudinal study

David Taylor-Robinson, Margaret Whitehead, Finn Diderichsen, Hanne Vebert Olesen, Tania Pressler, Rosalind L. Smyth, Peter Diggle

Research output: Contribution to journalArticle

Abstract

Background: Forced expiratory volume in 1 s as a percentage of predicted (%FEV1) is a key outcome in cystic fibrosis (CF) and other lung diseases. As people with CF survive for longer periods, new methods are required to understand the way %FEV1 changes over time. An up to date approach for longitudinal modelling of %FEV1 is presented and applied to a unique CF dataset to demonstrate its utility at the clinical and population level. Methods and findings: The Danish CF register contains 70 448%FEV1 measures on 479 patients seen monthly between 1969 and 2010. The variability in the data is partitioned into three components (between patient, within patient and measurement error) using the empirical variogram. Then a linear mixed effects model is developed to explore factors influencing %FEV1 in this population. Lung function measures are correlated for over 15 years. A baseline %FEV1 value explains 63% of the variability in %FEV1 at 1 year, 40% at 3 years, and about 30% at 5 years. The model output smooths out the short-term variability in %FEV1 (SD 6.3%), aiding clinical interpretation of changes in %FEV1. At the population level significant effects of birth cohort, pancreatic status and Pseudomonas aeruginosa infection status on %FEV1 are shown over time. Conclusions: This approach provides a more realistic estimate of the %FEV1 trajectory of people with chronic lung disease by acknowledging the imprecision in individual measurements and the correlation structure of repeated measurements on the same individual over time. This method has applications for clinicians in assessing prognosis and the need for treatment intensification, and for use in clinical trials.

Original languageEnglish (US)
Pages (from-to)860-866
Number of pages7
JournalThorax
Volume67
Issue number10
DOIs
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

Cystic Fibrosis
Longitudinal Studies
Lung Diseases
Population
Pseudomonas Infections
Cohort Effect
Forced Expiratory Volume
Pseudomonas aeruginosa
Chronic Disease
Clinical Trials
Parturition
Lung
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Taylor-Robinson, D., Whitehead, M., Diderichsen, F., Olesen, H. V., Pressler, T., Smyth, R. L., & Diggle, P. (2012). Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: A longitudinal study. Thorax, 67(10), 860-866. https://doi.org/10.1136/thoraxjnl-2011-200953

Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis : A longitudinal study. / Taylor-Robinson, David; Whitehead, Margaret; Diderichsen, Finn; Olesen, Hanne Vebert; Pressler, Tania; Smyth, Rosalind L.; Diggle, Peter.

In: Thorax, Vol. 67, No. 10, 10.2012, p. 860-866.

Research output: Contribution to journalArticle

Taylor-Robinson, D, Whitehead, M, Diderichsen, F, Olesen, HV, Pressler, T, Smyth, RL & Diggle, P 2012, 'Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: A longitudinal study', Thorax, vol. 67, no. 10, pp. 860-866. https://doi.org/10.1136/thoraxjnl-2011-200953
Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen HV, Pressler T, Smyth RL et al. Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: A longitudinal study. Thorax. 2012 Oct;67(10):860-866. https://doi.org/10.1136/thoraxjnl-2011-200953
Taylor-Robinson, David ; Whitehead, Margaret ; Diderichsen, Finn ; Olesen, Hanne Vebert ; Pressler, Tania ; Smyth, Rosalind L. ; Diggle, Peter. / Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis : A longitudinal study. In: Thorax. 2012 ; Vol. 67, No. 10. pp. 860-866.
@article{51f78621b6d34e2084224fd0dd26c802,
title = "Understanding the natural progression in {\%}FEV1 decline in patients with cystic fibrosis: A longitudinal study",
abstract = "Background: Forced expiratory volume in 1 s as a percentage of predicted ({\%}FEV1) is a key outcome in cystic fibrosis (CF) and other lung diseases. As people with CF survive for longer periods, new methods are required to understand the way {\%}FEV1 changes over time. An up to date approach for longitudinal modelling of {\%}FEV1 is presented and applied to a unique CF dataset to demonstrate its utility at the clinical and population level. Methods and findings: The Danish CF register contains 70 448{\%}FEV1 measures on 479 patients seen monthly between 1969 and 2010. The variability in the data is partitioned into three components (between patient, within patient and measurement error) using the empirical variogram. Then a linear mixed effects model is developed to explore factors influencing {\%}FEV1 in this population. Lung function measures are correlated for over 15 years. A baseline {\%}FEV1 value explains 63{\%} of the variability in {\%}FEV1 at 1 year, 40{\%} at 3 years, and about 30{\%} at 5 years. The model output smooths out the short-term variability in {\%}FEV1 (SD 6.3{\%}), aiding clinical interpretation of changes in {\%}FEV1. At the population level significant effects of birth cohort, pancreatic status and Pseudomonas aeruginosa infection status on {\%}FEV1 are shown over time. Conclusions: This approach provides a more realistic estimate of the {\%}FEV1 trajectory of people with chronic lung disease by acknowledging the imprecision in individual measurements and the correlation structure of repeated measurements on the same individual over time. This method has applications for clinicians in assessing prognosis and the need for treatment intensification, and for use in clinical trials.",
author = "David Taylor-Robinson and Margaret Whitehead and Finn Diderichsen and Olesen, {Hanne Vebert} and Tania Pressler and Smyth, {Rosalind L.} and Peter Diggle",
year = "2012",
month = "10",
doi = "10.1136/thoraxjnl-2011-200953",
language = "English (US)",
volume = "67",
pages = "860--866",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "10",

}

TY - JOUR

T1 - Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis

T2 - A longitudinal study

AU - Taylor-Robinson, David

AU - Whitehead, Margaret

AU - Diderichsen, Finn

AU - Olesen, Hanne Vebert

AU - Pressler, Tania

AU - Smyth, Rosalind L.

AU - Diggle, Peter

PY - 2012/10

Y1 - 2012/10

N2 - Background: Forced expiratory volume in 1 s as a percentage of predicted (%FEV1) is a key outcome in cystic fibrosis (CF) and other lung diseases. As people with CF survive for longer periods, new methods are required to understand the way %FEV1 changes over time. An up to date approach for longitudinal modelling of %FEV1 is presented and applied to a unique CF dataset to demonstrate its utility at the clinical and population level. Methods and findings: The Danish CF register contains 70 448%FEV1 measures on 479 patients seen monthly between 1969 and 2010. The variability in the data is partitioned into three components (between patient, within patient and measurement error) using the empirical variogram. Then a linear mixed effects model is developed to explore factors influencing %FEV1 in this population. Lung function measures are correlated for over 15 years. A baseline %FEV1 value explains 63% of the variability in %FEV1 at 1 year, 40% at 3 years, and about 30% at 5 years. The model output smooths out the short-term variability in %FEV1 (SD 6.3%), aiding clinical interpretation of changes in %FEV1. At the population level significant effects of birth cohort, pancreatic status and Pseudomonas aeruginosa infection status on %FEV1 are shown over time. Conclusions: This approach provides a more realistic estimate of the %FEV1 trajectory of people with chronic lung disease by acknowledging the imprecision in individual measurements and the correlation structure of repeated measurements on the same individual over time. This method has applications for clinicians in assessing prognosis and the need for treatment intensification, and for use in clinical trials.

AB - Background: Forced expiratory volume in 1 s as a percentage of predicted (%FEV1) is a key outcome in cystic fibrosis (CF) and other lung diseases. As people with CF survive for longer periods, new methods are required to understand the way %FEV1 changes over time. An up to date approach for longitudinal modelling of %FEV1 is presented and applied to a unique CF dataset to demonstrate its utility at the clinical and population level. Methods and findings: The Danish CF register contains 70 448%FEV1 measures on 479 patients seen monthly between 1969 and 2010. The variability in the data is partitioned into three components (between patient, within patient and measurement error) using the empirical variogram. Then a linear mixed effects model is developed to explore factors influencing %FEV1 in this population. Lung function measures are correlated for over 15 years. A baseline %FEV1 value explains 63% of the variability in %FEV1 at 1 year, 40% at 3 years, and about 30% at 5 years. The model output smooths out the short-term variability in %FEV1 (SD 6.3%), aiding clinical interpretation of changes in %FEV1. At the population level significant effects of birth cohort, pancreatic status and Pseudomonas aeruginosa infection status on %FEV1 are shown over time. Conclusions: This approach provides a more realistic estimate of the %FEV1 trajectory of people with chronic lung disease by acknowledging the imprecision in individual measurements and the correlation structure of repeated measurements on the same individual over time. This method has applications for clinicians in assessing prognosis and the need for treatment intensification, and for use in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84866120215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866120215&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2011-200953

DO - 10.1136/thoraxjnl-2011-200953

M3 - Article

VL - 67

SP - 860

EP - 866

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 10

ER -